A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

July 13, 2021

Primary Completion Date

February 13, 2026

Study Completion Date

February 10, 2027

Conditions
Prostatic Neoplasms
Interventions
DRUG

JNJ-78278343

JNJ-78278343 will be administered.

Trial Locations (17)

10032

ACTIVE_NOT_RECRUITING

Columbia University Medical Center Herbert Irving Pavilion, New York

10065

ACTIVE_NOT_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

13005

COMPLETED

APHM Hopital Timone, Marseille

28040

RECRUITING

Hosp Univ Fund Jimenez Diaz, Madrid

28050

COMPLETED

Hosp Univ Hm Sanchinarro, Madrid

29010

RECRUITING

Hosp Virgen de La Victoria, Málaga

69373

RECRUITING

Centre Leon Berard, Lyon

94800

RECRUITING

Institut Gustave Roussy, Villejuif

100191

ACTIVE_NOT_RECRUITING

Peking University Third Hospital, Beijing

325399

ACTIVE_NOT_RECRUITING

First Affiliated Hospital Of Wenzhou Medical College, Wenzhou

400030

ACTIVE_NOT_RECRUITING

Chongqing University Cancer Hospital, Chongqing

510710

ACTIVE_NOT_RECRUITING

Sun Yat Sen University Cancer Center, Guangzhou

98195-9472

ACTIVE_NOT_RECRUITING

University of Washington, Seattle

277 8577

ACTIVE_NOT_RECRUITING

National Cancer Center Hospital East, Kashiwa

232 0024

ACTIVE_NOT_RECRUITING

Yokohama City University Medical Center, Yokohama

1066 CX

COMPLETED

Antoni van Leeuwenhoek, Amsterdam

3015 GD

COMPLETED

Erasmus MC, Rotterdam

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY